Asia Pacific Diabetic Retinopathy Market has been estimated at USD 1.67 billion in 2018 and is projected to reach USD 2.44 billion by 2023, at a CAGR of 7.94% during the forecast period from 2018 to 2023.
Asia is predicted to show wealthy growth in the forecast period. Within the Asian region, the western pacific region accounts for larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies are huge pool of patients and increasing support and funding given by the government.
Diabetic retinopathy is considered as a severe sight-threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.
Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming years. Rising medical procedures due to the high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of retinopathy drug market in the future.
In addition, based on geography the Asia Pacific Diabetic Retinopathy Market is analyzed under the regions of India, China, Japan, Australia, and South Korea. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. The augmented occurrence of diabetes, lack of diagnosis at the right time, and non-compliant retinal screening of diabetic patients are predictable to drive the growth of non-proliferative diabetic retinopathy market share.
This Research Report segmented and sub-segmented the Asia Pacific Diabetic Retinopathy Market into the following categories:
By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Intraocular Steroid Injection, Laser Surgery, And Vitrectomy.
By Indication: Non-Proliferative Diabetic Retinopathy (NPDR) (Mild, Moderate And Severe) And Proliferative Diabetic Retinopathy (PDR))
By End User: Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers
By Country: India, China, Japan, Australia, and South Korea, Rest of Apac.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.1.4 Vitrectomy
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.1.1 Mild
5.2.1.2 Moderate
5.2.1.3 Severe
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
